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Successful treatment of persistent bronchorrhea by gefitinib 
in a case with Recurrent Bronchioloalveolar Carcinoma: a case 
report
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Abstract
Background: Bronchorrhea is one of late complaints in patients with bronchioloalveolar
carcinoma (BAC) and hampers their quality of life. Although an effective treatment for
bronchorrhea in these patients has not been established, recently we have treated effectively one
case of persistent bronchorrhea associated with clinical recurrent BAC with gefitinib (ZD1839,
'Iressa™'; AstraZeneca Japan; Osaka, Japan).
Case Presentation: A 63-year-old Japanese female had undergone left pneumonectomy with
radical lymph node dissection (ND2a) for diffuse type bronchioloalveolar carcinoma originated in
left lower lobe. Multiple pulmonary metastases in right lung were found one year after operation.
Pulmonary metastatic lesion has grown and she complained of progressive symptoms of massive
watery sputum and dyspnea, four years after operation. Although her symptom was getting worse
in spite of routine treatment, it completely disappeared within 2 weeks of starting oral gefitinib.
Thereafter, she has been symptom-free and shows good partial response on repeat scan after 9
months of oral gefitinib.
Conclusions: The dramatic remission of persistent bronchorrhea by gefitinib in the presented
case suggests that gefitinib might be a promising option for bronchioloalveolar carcinoma,
particularly in cases with severe bronchorrhea. Although it is not possible to comment on whether
the improvement came from tumor cell death itself or suppressive effect of mucin synthesis by the
epidermal growth factor receptor-tyrosine kinase inhibitory action.
Background
Gefitinib is an oral active, selective epidermal growth fac-
tor receptor-tyrosine kinase inhibitor (EGFR-TKI) [1],
which was first approved in Japan for patients with non-
small cell lung cancer on July 5, 2002. It is very interesting
that gefitinib is more effective in female patients with ade-
Published: 01 July 2003
World Journal of Surgical Oncology 2003, 1:8
Received: 23 April 2003
Accepted: 01 July 2003
This article is available from: http://www.wjso.com/content/1/1/8
© 2003 Takao et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Page 1 of 3
(page number not for citation purposes)
World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/8nocarcinoma than the others [2]. We describe here case of
a female successfully treated with gefitinib for her persist-
ent bronchorrhea due to recurrent multiple pulmonary
bronchioloalveolar carcinoma (BAC) following left
pneumonectomy.
Case Presentation
A 63-year-old Japanese female underwent left pneumon-
ectomy with radical lymph node dissection (ND2a) on
March 16, 1998, for diffuse type BAC originating in left
lower lobe, which was p-T2N0M1, stage IV disease with
intrapulmonary metastasis to left upper lobe (pm2). She
was thereafter followed with oral UFT (5-FU derivative
"tegafur" and uracil at a molar ratio of 1:4; Taiho Pharma-
ceutical Co., Ltd., Tokyo, Japan) at 400 mg/day, because
she refused to be treated with adjuvant intravenous chem-
otherapy. On March 12, 1999, multiple small pulmonary
metastases in the right lung (S5 and S6) were found on a
follow-up computerized tomographic scanning (CT),
although she was asymptomatic. As these pulmonary
metastases have grown slowly but constantly, oral etopo-
side 25 mg/day was added since April 10, 2001, she
refused the usage of intravenous anti-cancer agents. She
gradually developed productive cough and dyspnea since
July 2001. Chest CT on June 25, 2002 revealed multiple
pneumonia-like consolidations on each lobe of the right
lung (Fig. 1).
Although sputum cytology failed to prove a definitive
pathological diagnosis of recurrence, her symptom and
radiological findings had never improved by antibiotics,
steroid and with interruption of oral anti-cancer therapy.
Because she had complained of progressive symptoms of
massive watery sputum and dyspnea, she was started on
oral gefitinib 250 mg/day on October 8, 2002. Her symp-
toms dramatically improved along with disappearance of
the abnormal diffuse shadow on chest radiograph two
week later. On December 3, 2002, 8 weeks after gefitinib
was started, almost complete remission of diffuse pulmo-
nary cloudy shadow was confirmed on chest CT (Fig. 2).
She is taking daily 250 mg gefitinib for 9 months and had
been very well without any signs of tumor progression or
adverse side effects.
Discussion
Gefitinib is an orally active, selective EGFR-TKI that blocks
signal transduction pathways implicated in proliferation
and survival of cancer cells [1]. Although the mechanism
has been uncertain, the response rate was significantly
higher in adenocarcinoma and female patients than in
squamous carcinoma and male ones in clinical experi-
ences with gefitinib for lung cancer including two rand-
omized double-blind phase II studies (IDEAL 1 and 2)
[2,3]. As clinical experience in Japan thereafter shows
same tendency that gefitinib is more effective in female
patients with adenocarcinoma, we tried gefitinib in this
case. The response was somewhat more rapid and power-
ful than we expected. It is also true that the clinical effect
is evident within the first few weeks if sensitive to gefitinib
[2].
Although we have no evidence of a recurrent BAC in this
case, we believe, such a quick response with gefitinib ther-
apy strongly suggest her symptom with pulmonary con-
solidation had come from recurrence rather than
infectious disease or drug-induced pneumonitis. It is
Chest CT scan taken on June 25, 2002 showing the lesionFigure 1
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Chest CT scan taken on December 3,2002, 8 weeks after gefitinib was startedFigure 2
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meaningful if histological type BAC was associated with a
higher response to gefitinib, because BAC that is usually
resistant against chemotherapy and radiation brings
respiratory failure and infection due to mucus hyper secre-
tion in the end. Of particular, an effective treatment for
refractory bronchorrhea in these patients has not been
established, although a few successful case reports are
available [4].
Our observation, although just single case report, may
raises the possibility that the response in bronchorrhea
due to BAC might be related to that association of the
selective EGFR-TKI inhibition by gefitinib, because EGFR
expression and activation is reported to cause goblet-cell
metaplasia from Clara cells and mucus hyper secretion in
the airway [5]. So that, while it is still unknown whether
the improvement of CT findings in our case comes from
tumor cell death itself or suppressive effect of mucin syn-
thesis by the EGFR-TKI action, the dramatic effect in our
case brought us the hypothesis that gefitinib might be the
promising option for BAC, of particular cases with severe
bronchorrhea.
Although one might be also anticipate a high response to
gefitinib in BAC subtype because BAC has even higher
coexpression of both EGFR and HER2 than adenocarci-
noma [6], clinical markers of gefitinib sensitivity should
be investigated along with molecular predictive marker.
Finally, in this sense, further investigations should be war-





Written consent was obtained from the patient for publication of study.
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